
Behind the Pipeline: Our R&D Strategy

Video featuring Kumar Singh Saikatendu, SVP, Translational Medicine

At Novavax, we are expanding our pipeline to realize the potential of our cutting-edge [Technology Platform](#). With our protein-based nanoparticles and Matrix-M® adjuvant, we have a strong foundation for innovation.

Kumar Singh Saikatendu, Head of our Translational Medicine team shares what excites him for the future of the Company, including the potential of [preclinical vaccine candidates](#) to address unmet needs, as well as the application of artificial intelligence and machine learning to accelerate the development of these candidates.